204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm designEhsan Ghorani,Matteo Quartagno,Fiona Blackhall, Mary O'Brien,Christian Ottensmeier,Elena Pizzo,James Spicer,Duncan Gilbert, Alex Baker, Philip Badman,Charlotte Milner-Watts, Paolo D. d'Arienzo,Adam Dangoor,Jason Adhikaree,Joanne Evans, Pollyanna Leite, Manjusha Keni,Nicola Steele,Fabio Gomes, Igor Gomez-RandulfeLung Cancer（2024）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
